See more : A.P. Møller – Mærsk A/S (MAERSK-B.CO) Income Statement Analysis – Financial Results
Complete financial analysis of AzurRx BioPharma, Inc. (AZRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AzurRx BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hariom Pipe Industries Limited (HARIOMPIPE.NS) Income Statement Analysis – Financial Results
- Jimoty, Inc. (7082.T) Income Statement Analysis – Financial Results
- Havells India Limited (HAVELLS.NS) Income Statement Analysis – Financial Results
- Fujian Yuanli Active Carbon Co.,Ltd. (300174.SZ) Income Statement Analysis – Financial Results
- Hemogenyx Pharmaceuticals Plc (HEMO.L) Income Statement Analysis – Financial Results
AzurRx BioPharma, Inc. (AZRX)
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5,888.00B | 8.68M | 4.99M | 2.40M | 2.50M | 1.40M |
| General & Administrative | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 20,544.76B | 0.00 | 210.00K | 7.69M | 4.13M | -4.73M |
| Operating Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | -3.33M |
| Cost & Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | 4.73M |
| Interest Income | 484.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5,840.61B | 433.94K | 101.85K | 875.20K | 5.94M | 1.59M |
| Depreciation & Amortization | 37.80K | 1.02M | 798.45K | 754.00K | 734.50K | 733.60K |
| EBITDA | -26,830.85B | -13.72M | -12.63M | -9.47M | -7.92M | -3.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26,432.77B | -14.74M | -13.43M | -10.08M | -6.63M | -4.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6,238.70B | -433.94K | -101.85K | -1.02M | -7.97M | -1.20M |
| Income Before Tax | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -398.08B | 0.00 | 0.00 | -140.00K | -2.03M | 386.11K |
| Net Income | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| EPS Diluted | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| Weighted Avg Shares Out | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
| Weighted Avg Shares Out (Dil) | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
3 Penny Stocks That Top Investors Are Buying Right Now
AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints
AZRX Stock: The Huge Trial News Lifting Little-Known AzurRX BioPharma Today
AzurRx BioPharma Shares Increase Over 40% Pre-Market: Why It Happened
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AZRX Stock Price Increases Over 30% Pre-Market: Details You Should Know
Source: https://incomestatements.info
Category: Stock Reports